NCT00115076View on ClinicalTrials.gov

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

August 4, 2003

Primary Completion Date

May 18, 2009

Study Completion Date

April 6, 2011

Conditions

Psoriasis

Interventions

DRUG

Efalizumab

24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection

Trial Locations (2)

10065

Rockefeller University, New York

The Rockefeller University, New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Rockefeller University

OTHER